177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors (Lu-Ca-S)
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors: a Randomized Phase II Study.
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Terminated
Following the publication in the Official Journal of the reclassification of the drug LUTATHERA in band H, it was decided to close the enrolment early on 30/Aug/19.
Other terminated trials from Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Breast Cancer · Phase PHASE1 · Jan 2025
- 68Ga-PSMA PET/CT Guided Prostate Biopsy · Phase NA · Sep 2024
- Neuroendocrine Tumors · Phase PHASE2 · Jan 2024
- Prostate Adenocarcinoma · Phase NA · May 2023
- Metastatic Castration Resistant Prostate Cancer (mCRPC) · Mar 2022
See all terminations from Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A PHASE2 clinical study on Gastro-entero-pancreatic Neuroendocrine Tumors, this trial is terminated or withdrawn. The trial is conducted by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS and has accumulated 11 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Terminated PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Mar 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Mar 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2019 — May 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
For direct contact, visit the study record on ClinicalTrials.gov .